IBIONasdaqPharmaceutical PreparationsUS GAAP · USD

iBio, Inc.

iBio, Inc. is a U.S.-based preclinical biotechnology company focused on discovering and developing precision antibodies for cardiometabolic and obesity-related diseases. The company uses an AI and machine learning drug discovery platform, and it also develops and licenses early-stage biologic candidates and related intellectual property.

Kysy yhtiöstä
Liikevaihto0,1milj. USD
−75,0 %v/v
Liikevoitto (EBIT)−35,1milj. USD
−88,9 %v/v
EBIT-marginaali−35 141,0%
−30 490,5 %-yks.v/v
Nettotulos−33,0milj. USD
−79,8 %v/v
Vapaa kassavirta−23,8milj. USD
−55,3 %v/v

Tilikausi 2026 · muutos edellisvuodesta

Kehitys 2021–2026

−60−40−20020milj. USD2021: 2,4 milj. USD2021: EBIT −31 milj. USD20212022: 2,4 milj. USD2022: EBIT −50 milj. USD20222023: 0,00 milj. USD2023: EBIT −29 milj. USD20232024: 0,23 milj. USD2024: EBIT −17 milj. USD20242025: 0,40 milj. USD2025: EBIT −19 milj. USD20252026: 0,10 milj. USD2026: EBIT −35 milj. USD20260,10−35
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
AI Drug Discovery Platform10 %

Computational platform used to identify and optimize novel biologics and precision antibodies.

Preclinical Antibody Programs55 %

Early-stage therapeutic candidates such as IBIO-600 and IBIO-610 aimed at cardiometabolic and obesity targets.

Licensing and Collaboration Revenue20 %

Revenue from research services, licenses, and partner collaborations tied to discovery assets.

Intellectual Property and Platform Assets15 %

Owned patents, know-how, and related assets that support development and partnering.

Asiakkaat

iBio’s direct customers are typically pharmaceutical and biotechnology partners that license programs, fund collaborations, or receive research services tied to its discovery platform. Its end markets are ultimately patients and physicians in cardiometabolic, obesity, and other therapeutic areas, but near-term monetization depends on partnering with larger drug developers. The company also relies on specialized suppliers and contract service providers to support discovery and preclinical work.

Pharmaceutical licensing partners

Large or mid-sized drug companies that may license iBio candidates or IP to advance development and commercialization.

Biotechnology collaborators

Smaller biotech firms or research groups that collaborate on discovery, validation, or target-specific programs.

Research services customers

Counterparties that pay for collaborative research, assay work, or related services tied to platform capabilities.

Future therapeutic end users

Patients and clinicians in cardiometabolic and obesity indications who would use approved products if programs succeed.

Strategia

iBio’s strategy is to advance a small number of preclinical antibody programs while using its AI platform to generate differentiated molecules for hard-to-drug targets. It also seeks collaborations and licenses that can monetize discovery assets before internal products reach commercialization. The company’s direction is shaped by the need to convert platform science into partnerable programs and longer-duration therapeutic value.

Advance preclinical pipeline assetsLyhyt aikaväli

Pipeline programs are the main source of future value and partnering leverage.

Expand AI-driven discovery outputKeskipitkä aikaväli

The platform is intended to generate novel biologics that can be licensed or developed.

Secure collaborations and licensesKeskipitkä aikaväli

Partnerships can fund development and create non-dilutive value from early assets.

Maantiede

iBio is headquartered in the United States and conducts its research and development primarily in San Diego. The company also uses third-party suppliers and collaborators, including international vendors, to support discovery and preclinical work. Its therapeutic programs are described as worldwide in scope, so future partnering and commercialization could extend beyond the U.S.

Riskit

iBio faces the typical risks of an early-stage biotech company: clinical and preclinical failure, regulatory uncertainty, and dependence on external capital and partners. Its platform and assets may never produce meaningful revenue, and the company is exposed to supplier concentration, IP impairment risk, and competitive pressure from better-funded drug developers.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Development-stage program failure1Capital access and dilution2Competitive and regulatory pressure3Partner and collaborator dependence4Supplier and outsourcing concentration5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Development-stage program failureVaikutus: KriittinenTodennäköisyys: Korkea

    The company is still preclinical, so scientific or translational setbacks could eliminate asset value.

    KohdistuuIBIO-600IBIO-610Other pipeline assets
  2. Capital access and dilutionVaikutus: KorkeaTodennäköisyys: Korkea

    Long-duration R&D requires external funding before product revenue is available.

    KohdistuuEquity issuanceWarrantsOther financing sources
  3. Competitive and regulatory pressureVaikutus: KorkeaTodennäköisyys: Korkea

    Larger biotech and pharma firms have more resources for R&D, trials, and approvals.

    Kohdistuu: AI drug discovery and precision antibody markets

  4. Partner and collaborator dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Some programs rely on licensees or collaborators to advance development and commercialization.

    Kohdistuu: Collaborative research and licensing arrangements

  5. Supplier and outsourcing concentrationVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Key materials and services are outsourced and may have long lead times or limited alternatives.

    KohdistuuLonza Sales AGTwist BioscienceOther third parties

Kirjanpito

Harkinnanvaraiset erät
Indefinite-lived intangible asset impairment

IBIO-101 valuation depends on probability-adjusted cash flows and discount rates, which can change materially.

Vaikutus: Could create non-cash impairment charges and affect equity value

Collaboration and license revenue recognition

Revenue is tied to services and partner arrangements, so timing depends on contract terms and performance obligations.

Vaikutus: Can cause uneven quarterly revenue

Fair value estimates and WACC

Management uses discounted cash flow and weighted-average cost of capital assumptions in valuation work.

Vaikutus: Affects asset carrying values and impairment conclusions

R&D expense classification

Consultants, outside services, NHP studies, and CMC activities are major cost drivers.

Vaikutus: Influences operating loss and comparability across periods

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

IO Biotech, Inc.

IOBTQ · Pharmaceutical Preparations

Inmune Bio, Inc.

INMB · Biological Products, (No Diagnostic Substances)

IN8bio, Inc

INAB · Biological Products, (No Diagnostic Substances)

Inovio Pharmaceuticals, Inc

INO · Pharmaceutical Preparations

OmniAb, Inc.

OABIW · Services-Commercial Physical & Biological Research

Veru Inc

VERU · Pharmaceutical Preparations

Päivitetty: 24.9.2026